PharmaShots Weekly Snapshots (Jan 25- 29, 2021)

 PharmaShots Weekly Snapshots (Jan 25- 29, 2021)

Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm for Drug Discovery and Development

Published: Jan 29, 2020 | Tags: Roche, Collaborate, Cambridge Quantum Computing, Develop, Quantum Algorithm, Drug, Discovery, Development

Janssen Reports Results of Amivantamab in P-I CHRYSALIS Study for Metastatic or Unresectable NSCLC and EGFR Exon 20 Insertion Mutations

Published: Jan 29, 2020 | Tags: Janssen, Reports, Results, Amivantamab, P-I, CHRYSALIS, Study,  Metastatic, Unresectable, NSCLC, EGFR, Exon 20, Insertion, Mutations

Lilly Signs a License Agreement with Asahi Kasei Pharma for AK1780 to Treat Chronic Pain

Published: Jan 29, 2020 | Tags: Lilly, Signs, License, Agreement, Asahi Kasei Pharma, AK1780, Treat, Chronic Pain

Bio-Thera Solutions Reports the US FDA’s Acceptance of BLA for BAT1706 (Proposed Biosimilar to Avastin)

Published: Jan 29, 2020 | Tags: Bio-Thera Solutions, Reports, US, FDA, Acceptance, BLA, BAT1706, (Proposed Biosimilar to Avastin)

Amgen Report Results of Sotorasib in P-II Study for KRAS G12C-Mutated Advanced NSCLC

Published: Jan 29, 2020 | Tags: Amgen, Report, Results, Sotorasib, P-II, Study, KRAS G12C, Mutated, Advanced, NSCLC

Merck Signs an Exclusive Worldwide License Agreement with Artiva to Develop CAR-NK Cell Therapies

Published: Jan 29, 2020 | Tags: Merck, Signs, Exclusive, Worldwide, License, Agreement, Artiva, Develop, CAR-NK Cell, Therapies

BioInvent Report Results of BI-1206 + Rituximab in P- I/IIa Study for Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma

Published: Jan 28, 2020 | Tags: BioInvent, Report, Results, BI-1206, Rituximab, P- I/IIa, Study,  Relapsed, Refractory, B-cell, Non-Hodgkin’s, Lymphoma

ImaginAb Signs a Multi-Year Non-Exclusive License Agreement with Neuvogen for CD8 ImmunoPET Technology

Published: Jan 28, 2020 | Tags: ImaginAb, Signs, Multi-Year, Non-Exclusive, License, Agreement,  Neuvogen, CD8, ImmunoPET, Technology

Regeneron’s REGEN-COV Antibody Cocktail Confirms its Effectiveness Against UK and South Africa SARS-CoV-2 Variants

Published: Jan 28, 2020 | Tags: Regeneron, REGEN-COV, Antibody, Cocktail, Confirms, Effectiveness, Against, UK, South Africa, SARS-CoV-2, Variants

Pfizer’s Xeljanz (tofacitinib) Fails to Meet its Co-Primary Endpoint in ORAL Surveillance Safety Study

Published: Jan 28, 2020 | Tags: Pfizer, Xeljanz (tofacitinib), Fails, Meet, Co-Primary, Endpoint, ORAL, Surveillance, Safety, Study

AstraZeneca Selects AI-Generated CKD Target Under its Collaboration with BenevolentAI

Published: Jan 28, 2020 | Tags: AstraZeneca, Selects, AI-Generated, CKD, Target, Collaboration, BenevolentAI

Eli Lilly Collaborates with GSK and VIR to Evaluate Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

Published: Jan 28, 2020 | Tags: Eli Lilly, Collaborates, GSK, VIR, Evaluate, Bamlanivimab (LY-CoV555), VIR-7831 (GSK4182136), COVID-19

Abbott’s Panbio Rapid Antigen Test Receives CE Mark for Mass COVID-19 Screening

Published: Jan 27, 2020 | Tags: Abbott, Panbio, Rapid, Antigen Test, Receives, CE, Mark, Mass, COVID-19, Screening

AbbVie’s Rinvoq (upadacitinib) Receives the EC’s Approval for Psoriatic Arthritis and Ankylosing Spondylitis

Published: Jan 27, 2020 | Tags: AbbVie, Rinvoq (upadacitinib), Receives, EC, Approval, Psoriatic Arthritis, Ankylosing Spondylitis

Regeneron Reports Results of REGEN-COV Antibody Cocktail Used as Passive Vaccine to Prevent COVID-19

Published: Jan 27, 2020 | Tags: Regeneron, Reports, Results, REGEN-COV, Antibody, Cocktail, Passive, Vaccine, Prevent, COVID-19

Shionogi Concludes a License Agreement with BioAge for BGE-175 to Control the Aggravation of COVID-19

Published: Jan 27, 2020 | Tags: Shionogi, Concludes, License, Agreement, BioAge, BGE-175, Control, Aggravation, COVID-19

Eli Lilly and AbCellera Report Results of Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV16) in P-II/III BLAZE-1 Study for Preventing COVID-19

Published: Jan 27, 2020 | Tags: Eli Lilly, AbCellera, Report, Results, Bamlanivimab (LY-CoV555), Etesevimab (LY-CoV16), P-II/III, BLAZE-1, Study, Preventing, COVID-19

Merck’s Keytruda (pembrolizumab) Receives EC’s Approval as 1L Treatment for Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer

Published: Jan 27, 2020 | Tags: Merck, Keytruda (pembrolizumab), Receives, EC, Approval, 1L, Treatment, Metastatic, Microsatellite, Instability-High (MSI-H), Mismatch Repair Deficient (dMMR), Colorectal Cancer

Ervaxx and Cardiff University Collaborate to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens

Published: Jan 25, 2020 | Tags: Ervaxx, Cardiff University, Collaborate, Develop, Novel T-cell, T-cell, Receptor-based, Immunotherapeutics, Targeting, Dark Antigens

Incyte Reports Acceptance and Priority Review of BLA for Retifanlimab to Treat Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)

Published: Jan 25, 2020 | Tags: Incyte, Reports, Acceptance, Priority Review, BLA, Retifanlimab, Treat, Patients, Squamous Cell Carcinoma, Anal Canal (SCAC)

Pfizer and BioNTech Signs an Agreement with Covax for Advance Purchase of Vaccine to Help Combat COVID-19

Published: Jan 25, 2020 | Tags: Pfizer, BioNTech, Signs, Agreement, Covax, Advance Purchase, Vaccine, Help, Combat, COVID-19

Aurinia Lupkynis (voclosporin) Receives US FDA’s Approval to Treat Adult Patients with Active Lupus Nephritis

Published: Jan 25, 2020 | Tags: Aurinia, Lupkynis (voclosporin), Receives, US, FDA, Approval, Treat, Adult, Patients, Active, Lupus Nephritis

P&G Signs a License Agreement with Rhinostics to Launch its Novel Nasal Swab into the Market for Rapid COVID-19 Testing and Address Supply Shortages

Published: Jan 25, 2020 | Tags: P&G, Signs, License, Agreement, Rhinostics, Launch, Novel, Nasal Swab, Market, Rapid, COVID-19, Testing, Address, Supply, Shortages

Exelixis Cabometyx (cabozantinib) + Opdivo (nivolumab) Receives US FDA’s Approval as a 1L Treatment for Patients with Advanced Renal Cell Carcinoma

Published: Jan 25, 2020 | Tags: Exelixis, Cabometyx (cabozantinib), Opdivo (nivolumab), Receives, US, FDA, Approval, 1L, Treatment, Patients, Advanced, Renal, Cell, Carcinoma

Related Post: PharmaShots Weekly Snapshots (Jan 18 – 22, 2021)

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on

Related post